Open AccessIntegrase Strand Transfer Inhibitor Start or Switch Impacts Learning in Women With HIV
Author(s) -
Jane A. O’Halloran,
Kunbo Wang,
Amanda B. Spence,
Dionna W. Williams,
Raha Dastgheyb,
Kathryn C. Fitzgerald,
Asante R. Kamkwalala,
Pauline M. Maki,
Anjali Sharma,
Deborah Gustafson,
Joel Milam,
Kathleen M. Weber,
Adaora A. Adimora,
Igho Ofotokun,
Margaret A. Fischl,
Deborah KonkleParker,
Cecile Delille Lahiri,
Anandi N. Sheth,
Yanxun Xu,
Leah H. Rubin
Publication year - 2021
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000002608
Subject(s) - dolutegravir , raltegravir , regimen , medicine , elvitegravir , psychology , clinical psychology , human immunodeficiency virus (hiv) , antiretroviral therapy , virology , viral load
Integrase strand transfer inhibitors (INSTIs) are first-line regimens for HIV treatment. We aimed to examine their impact on cognitive performance and depressive symptoms in women with HIV (WWH).